warning about possible hepatotoxicity in diabetics taking Rezulin (troglitazone)

December 1997

    Parke-Davis is warning about possible hepatotoxicity in diabetics taking Rezulin (troglitazone).

    This is important. Rezulin has been given to about half a million patients since it came out last January.

    But now there are 35 reports of liver damage...resulting in one liver transplant and one death.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote